State-of-the-art Lecture Immunotherapy: Impact from Surgeon’s Point of View

London, England (UroToday.com) Dr. von Rundstedt provided the surgeon’s point of view regarding immune therapy at this morning’s EAU 2017 thematic session on Immuno-oncology. As Dr. von Rundstedt aptly and humorously described “Immune therapy for surgeons is kind of like Mary Poppins: we did not expect to see her, she is full of surprises, we don’t know what to think of her, we may not always understand her, and she uses strange names!”

EAU 2017: State-of-the-art Lecture Immunotherapy: Impact from Oncologist’s Point of View

London, England (UroToday.com) This morning’s thematic session on Immuno-oncology for Renal and Urothelial Cancer at the EAU 2017 Annual Congress was highly anticipated given the many exciting studies that have been published in the last number of months. Dr. Thomas Powles from London began the session by giving the medical oncologist’s viewpoint, specifically with regards to renal cancer.

EAU 2017: A nomogram for prediction of local cancer recurrence after primary prostate cryoablation

London, England (UroToday.com) Nomograms are clinically relevant tools able to be used by the clinician to help counsel patients and predict outcomes. In the setting of focal therapy for localized prostate cancer, nomograms can serve an important role in helping to identify risk of recurrence or progression. As the technology develops and the follow-up data becomes more robust, we will likely need new nomograms along the way.

EAU 2017: First repeated biopsy represents the most informative predictor of progression-free survival at 3 years follow-up in patients included in an active surveillance protocol for low-risk prostate cancer

London, England (UroToday.com) Active surveillance has become standard of care for low-volume, low-risk clinically localized prostate cancer. However, despite adequate assessment, approximately 20-30% of men placed on active surveillance will progress to needing intervention; a portion (approximately 1/3) of those are due to patient choice, but the rest are due to progression of disease. Being able to identify these patients at risk of progression is important for counseling and decision making. Additionally, by identify those not likely to progress, reduced frequency of biopsies may be considered.

EAU 2017: A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study

London, England (UroToday.com) Focal therapy for prostate cancer continues to develop rapidly. Early outcomes from multiple institutions have been promising. However, without long-term data, it remains hard to draw conclusions.

EAU 2017: Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy

London, England (UroToday.com) Focal therapy for prostate cancer continues to develop rapidly. Early outcomes from multiple institutions have been promising. However, without long-term data, it remains hard to draw conclusions.

EAU 2017: Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study

London, England (UroToday.com) Novel techniques and therapies continue to be developed within the field of focal therapy. While early results seem to be promising, long-term outcomes result are still pending. However, in the meantime, newer agents and slight modifications continue to be developed to optimize this technology.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe